Publications involving nanobodies
Jenster LM, Lange KL, Normann S, vom Hemdt A, Wuerth JD, Schiffelers LDJ, Tesfamariam YM, Gohr FN, Klein L, Kaltheuner IH, Lapp DJ, Mayer J, Moecking J, Ploegh HL, Latz E, Geyer M, Kümmerer BM, Schmidt FI. P38 kinases mediate NLRP1 inflammasome activation after ribotoxic stress response and virus infection. bioRxiv 2022.01.24.477423; doi: https://doi.org/10.1101/2022.01.24.477423
Peter MF, Depping P, Schneberger N, Severi E, Gatterdam K, Tindall S, Durand A, Heinz V, Koenig PA, Geyer M, Ziegler C, Thomas GH, Hagelueken G. The structure of HiSiaQM defines the architecture of tripartite ATP-independent periplasmic (TRAP) transporters. bioRxiv 2021.12.03.471092; doi: https://doi.org/10.1101/2021.12.03.471092
Krämer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-García R, Schulte-Schrepping J, Kaiser KM, Rieke GJ, Bischoff J, Monin MB, Hoffmeister C, Schlabe S, De Domenico E, Reusch N, Händler K, Reynolds G, Blüthgen N, Hack G, Finnemann C, Nischalke HD, Strassburg CP, Stephenson E, Su Y, Gardner L, Yuan D, Chen D, Goldman J, Rosenstiel P, Schmidt SV, Latz E, Hrusovsky K, Ball AJ, Johnson JM, Koenig PA, Schmidt FI, Haniffa M, Heath JR, Kümmerer BM, Keitel V, Jensen B, Stubbemann P, Kurth F, Sander LE, Sawitzki B; Deutsche COVID-19 OMICS Initiative (DeCOI), Aschenbrenner AC, Schultze JL, Nattermann J. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.
Immunity. 2021 Nov 9;54(11):2650-2669.e14
Koenig PA, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Tödtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu X, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hällberg BM, Wu NC, Schmidt FI. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021 Feb 12;371(6530):eabe6230.
Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S*, Fiedler W*. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Int J Mol Sci. 2021 Nov 29;22(23):12919.
Baum N, Eggers M, Koenigsdorf J, Menzel S, Hambach J, Staehler T, Fliegert R, Kulow F, Adam G, Haag F, Bannas P, Koch-Nolte F. Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells. Front Immunol. 2021 Sep 3;12:703574.
Hambach J, Stähler T, Eden T, Wendt D, Tode N, Haag F, Tolosa E, Altfeld M, Fathi A, Dahlke C, Addo MM, Menzel S*, Koch-Nolte F*. A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike protein. Immun Inflamm Dis. 2021 Sep;9(3):905-917.
Hansen JN, Kaiser F, Klausen C, Stüven B, Chong R, Bönigk W, Mick DU, Möglich A, Jurisch-Yaksi N, Schmidt FI, Wachten D. Nanobody-directed targeting of optogenetic tools to study signaling in the primary cilium.
Elife. 2020 Jun 24;9:e57907.
Baum N, Fliegert R, Bauche A, Hambach J, Menzel S, Haag F, Bannas P, Koch-Nolte F. Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells. Cancers (Basel). 2020 Dec 30;13(1):76.
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics. 2020 Feb 3;10(6):2645-2658
Bergmann P, Garcia de Paco E, Rissiek B, Menzel S, Dubberke G, Hua J, Rassendren F, Ulmann L, Koch-Nolte F. Generation and Characterization of Specific Monoclonal Antibodies and Nanobodies Directed Against the ATP-Gated Channel P2X4. Front Cell Neurosci. 2019 Nov 12;13:498.
Koch-Nolte F, Eichhoff A, Pinto-Espinoza C, Schwarz N, Schäfer T, Menzel S, Haag F, Demeules M, Gondé H, Adriouch S. Novel biologics targeting the P2X7 ion channel. Curr Opin Pharmacol. 2019 Aug;47:110-118.
Schmidt FI. Phenotypic Lentivirus Screens to Identify Antiviral Single Domain Antibodies. Methods Mol Biol. 2018;1836:139-158.
Ingram JR, Schmidt FI, Ploegh HL. Exploiting Nanobodies’ Singular Traits. Annu Rev Immunol. 2018 Apr 26;36:695-715.
Menzel S, Schwarz N, Haag F, Koch-Nolte F. Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.Front Pharmacol. 2018 Mar 27;9:266.
Eden T, Menzel S, Wesolowski J, Bergmann P, Nissen M, Dubberke G, Seyfried F, Albrecht B, Haag F, Koch-Nolte F. A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation. Front Immunol. 2018 Jan 23;8:1989.
Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Röckendorf J, Menzel S, Albrecht B, Haag F, Stortelers C, Bannas P, Koch-Nolte F. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.Front Immunol. 2018 Nov 19;9:2553.
Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, Dougan M. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10184-10189.
Hanke L, Schmidt FI, Knockenhauer KE, Morin B, Whelan SP, Schwartz TU, Ploegh HL. Vesicular stomatitis virus N protein-specific single-domain antibody fragments inhibit replication. EMBO Rep. 2017 Jun;18(6):1027-1037.
Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao YJ, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Sci Rep. 2017 Oct 30;7(1):14289.
Hanke L, Knockenhauer KE, Brewer RC, van Diest E, Schmidt FI, Schwartz TU, Ploegh HL. The Antiviral Mechanism of an Influenza A Virus Nucleoprotein-Specific Single-Domain Antibody Fragment. mBio. 2016 Dec 13;7(6):e01569-16.
Schmidt FI, Hanke L, Morin B, Brewer R, Brusic V, Whelan SP, Ploegh HL. Phenotypic lentivirus screens to identify functional single domain antibodies. Nat Microbiol. 2016 Jun 20;1(8):16080. doi: 10.1038/nmicrobiol.2016.80.PMID: 27573105
Schmidt FI, Lu A, Chen JW, Ruan J, Tang C, Wu H, Ploegh HL. A single domain antibody fragment that recognizes the adaptor ASC defines the role of ASC domains in inflammasome assembly. J Exp Med. 2016 May 2;213(5):771-90. doi: 10.1084/jem.20151790.
Ashour J, Schmidt FI, Hanke L, Cragnolini J, Cavallari M, Altenburg A, Brewer R, Ingram J, Shoemaker C, Ploegh HL. Intracellular expression of camelid single-domain antibodies specific for influenza virus nucleoprotein uncovers distinct features of its nuclear localization. J Virol. 2015 Mar;89(5):2792-800
Unger M, Eichhoff AM, Schumacher L, Strysio M, Menzel S, Schwan C, Alzogaray V, Zylberman V, Seman M, Brandner J, Rohde H, Zhu K, Haag F, Mittrücker HW, Goldbaum F, Aktories K, Koch-Nolte F. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep. 2015 Jan 19;5:7850.
Patents
Schmidt FI, Koenig PA. PCT-Anmeldung SARS-CoV-2 Nanobodies 11/2021 [EP-Anmeldung 2020]
Koch-Nolte F, Magnus T, Haag F, Rissiek B, Duan Y, Menzel S. Antigen-binding polypeptides against CD73 EP21192286.9 2021
Koch-Nolte F, Magnus T, Haag F, Rissiek B, Duan Y, Menzel S. Antigen-binding polypeptides against CD39 EP21192287.7 2021
Koch-Nolte F, Eden T, Wesolowski J, Menzel S. VHH-containing heavy chain antibody and production thereof US 2020/0062833 A1 2020
Hottiger M O, Leutert M, Koch-Nolte F, Menzel S. ARTC1 ligands for cancer treatment EP20177397 2017
Koch-Nolte F, Schütze K, Bannas P, Fumey F, Schriewer L, Menzel S. Improving the cytotoxicity of antibodies by combining two or more single domain antibodies. US 65/253318 2016